Table 2 Course characteristics and infection outcomes (N = 127)
All (N = 127) | Intensive treatment (N = 101) | APL-specific treatment (N = 99) | |
|---|---|---|---|
Course characteristics | |||
Number with neutropenia (ANC <0.5 × 109) at start of course (%) | 27 (21.3) | 27 (26.7) | 21 (21.2) |
Median days with neutropenia1(IQR) | 7.5 (0.0, 19.0) | 11.0 (0.0, 20.0) | 3.0 (0.0, 18.0) |
Median days receiving systemic corticosteroids (IQR) | 0.0 (0.0, 5.0) | 0.0 (0.0, 6.0) | 0.0 (0.0, 3.0) |
Median corticosteroid dose1 (IQR) | 0.0 (0.0, 29.7) | 0.0 (0.0, 38.4) | 0.0 (0.0, 5.7) |
Supportive care | |||
Co-trimoxazole prophylaxis (%) | 89 (70.1) | 71 (70.3) | 77 (77.8) |
Other antibacterial prophylaxis (%) | 0 | 0 | 0 |
Fluconazole prophylaxis (%) | 30 (23.6) | 27 (26.7) | 18 (18.2) |
Infection outcomes 2 | |||
Sterile site microbiologically documented infection (%) | 15 (11.8) | 14 (13.9) | 9 (9.1) |
Sterile site Gram-positive (%) | 12 (9.5) | 11 (10.9) | 7 (7.1) |
Sterile site Gram-negative (%) | 4 (3.2) | 4 (4.0) | 2 (2.0) |
Sterile site fungus (%) | 2 (1.6) | 2 (2.0) | 2 (2.0) |
Bacteremia (%) | 11 (8.7) | 10 (9.9) | 7 (7.1) |
Clinically documented infection (%) | 30 (23.6) | 24 (23.8) | 26 (26.3) |
Sepsis | 8 (6.3) | 7 (6.9) | 8 (8.1) |
Infectious death | 1 (0.8) | 1 (1.0) | 1 (1.0) |